Background. Relatively limited epidemiological data are available regarding the prognosis of congestive heart failure (CHF) and temporal changes in survival after its onset in a population-based setting.
failure, and calendar year of first diagnosis on survival after its development.
Methods

Study Population
In 1948, 5,209 residents of Framingham, Mass., aged 28-62 years, were enrolled in a prospective epidemiological study. The selection criteria and study design have been detailed elsewhere.89 Members of this original cohort of the Framingham Heart Study have subsequently been evaluated at 2-year intervals with medical histories, physical examinations, and laboratory tests, including blood chemistries and ECGs. In 1971, children of the original study participants and the spouses of these children were entered in the Framingham Offspring Study.10 Follow-up evaluations were performed on members of the offspring study 8 and 12 years after enrollment. The 5, 209 members of the original cohort and the 5,135 members of the offspring study were eligible for inclusion in the current investigation.
Seventeen members of the original study cohort with CHF diagnosed at the time of their first examination (prevalence cases) were excluded from this analysis. In addition, to avoid inclusion of overly high-risk offspring subjects, 881 members of the offspring study with only one natural parent in the original cohort were excluded; such individuals were preferentially enrolled if that parent had a high-risk lipid profile or premature cardiovascular disease.
Definitions
At each examination, interim cardiovascular disease events were identified by medical history, physical examination, 12-lead ECG, and review of medical records. Hospital and physician records were obtained for subjects who did not appear for an examination and were scrutinized for evidence of cardiovascular disease. All possible cardiovascular events were reviewed by three physicians who examined the relevant records using established Framingham Heart Study protocols.
Coronary heart disease (CHD) events included in this study are angina pectoris, coronary insufficiency (unstable angina), and myocardial infarction; the criteria for these events have been described previously.11 A patient was considered to have preexisting valvular heart disease (VHD) if the examining physician noted a systolic murmur louder than grade II/VI, a diastolic murmur, or a palpable thrill at one or more examinations before the onset of heart failure. Radiographic and echocardiographic data were not used in the diagnosis of CHD or VHD. Hypertension (HTN) was defined as the presence of 1) either a systolic blood pressure .160 mm Hg or a diastolic blood pressure .95 mm Hg on each of two successive determinations by a physician during a given examination or 2) ongoing pharmacological treatment of a previously elevated blood pressure. Subjects with a fasting blood glucose of .7.77 mmol/L (140 mg/dL) or a random blood glucose of .11.10 mmol/L (200 mg/dL) were considered to be diabetic, as were individuals using insulin or oral hypoglycemic agents. Definite electrocardiographic left ventricular hypertrophy (LVH) was diagnosed upon review of ECGs from examinations before the onset of heart failure if voltage criteria for LVH were fulfilled in an ECG exhibiting lateral ST-segment depression or T wave flattening or inversion; ECGs with LVH by voltage criteria but without ST-segment or T wave abnormality were classified as showing "possible LVH.'12 The diagnosis of radiographic generalized cardiac enlargement was made if the heart shadow was rounded and expanded both to the left and the right, suggesting dilation of multiple chambers.12 Body mass index, a measure of obesity, was computed as the weight (in kilograms) divided by the height (in meters) squared. Serum and plasma cholesterol levels were determined using the method of Abell and Kendall.13
Criteria for Congestive Heart Failure
A diagnosis of CHF was established by the simultaneous presence of at least two major criteria or one major criterion in conjunction with two minor criteria (Table 1) .14 Minor criteria were acceptable only if they could not be attributed to another medical condition (such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or nephrotic syndrome). The same criteria for heart failure were used throughout the 40year follow-up of study subjects.
Cases of CHF were attributed to various causes using the following hierarchy: 1) CHF in individuals with CHD at or before the onset of heart failure was considered the result of CHD; 2) VHD was presumed to The diagnosis of congestive heart failure required that two major or one major and two minor criteria be present concurrently. Minor criteria were acceptable only if they could not be attributed to another medical condition. at any examination before the onset of heart failure who were free of CHD; 3) cases were attributed to HTN if the individual had an antecedent diagnosis of HTN without prior evidence of CHD or VHD; 4) all other cases of CHF without documented CHD, VHD, or HTN before the onset of heart failure were attributed to other or unknown causes. There was no category for idiopathic dilated cardiomyopathy because echocardiographic and ventriculographic data were not uniformly obtained.
Statistical Analysis
Age-adjusted differences in the proportion of cases of CHF attributed to CHD, VHD, and HTN by sex and calendar decade were examined using Cochran-Mantel-Haenszel statistics stratified by 5-year age groups. Univariate comparisons of clinical characteristics among cases of heart failure that were due to the various attributable causes were performed using x2 statistics for dichotomous variables and the Kruskal-Wallis test for continuous variables. To protect against false-positive associations, only clinical characteristics with significant disparities over all cause groups (i.e., p<O.05 by x2 or Kruskal-Wallis test statistics) were subjected to further pairwise comparisons between cause groups with two-tailed Fisher's exact tests and Wilcoxon rank sum tests.
For analysis of survival, univariate Cox proportional hazards models were used to investigate the relations between survival and sex, several clinical variables, age be the cause of CHF in subjects with evidence of VHD and calendar year at the time of first diagnosis of CHF, and attributable cause of heart failure. 15 The results of these analyses are expressed as hazards ratios, which are statistics similar to the odds ratio and relative risk. Because the study population was aging during the study period, in those models investigating the effect of calendar year, analyses were stratified by age at diagnosis (in 5-year age groups); similarly, in models evaluating age at diagnosis, analyses were stratified by calendar year (expressed in half-decades). Except for the model exploring the effect of sex on survival, men and women were analyzed separately. Separate models were used to investigate survival after heart failure specifically attributed to CHD, VHD, and HTN. Median survival times and survival rates at 90 days and at 1, 2, 4, 5, and 10 years after the onset of CHF were estimated using Kaplan-Meier methods. To facilitate comparison with results from heart failure intervention trials, the survival analyses were repeated excluding subjects who died or who were lost to follow-up during the first 90 days after the diagnosis of heart failure.
The software package S-PLUS (Statistical Sciences, Inc., Seattle, Wash.) was used for the survival analyses; estimation of the standard error for survival curves and all other computations were performed utilizing the SAS SYSTEM (SAS Institute Inc., Cary, N.C.). A two-sided probability value of 0.05 or less was required for statistical significance. Numerical values are expressed as mean± SD, except for survival rates from Kaplan-Meier analyses, which are expressed as mean±SE (standard error).
Results
Study Population
Characteristics of the 9,405 Framingham Heart Study subjects eligible for this analysis are summarized in Table 2 . The median length of follow-up was 14.8 years. During the period of observation, 652 subjects developed CHF (mean age, 70.0±10.8 years; range, 32-95 years; Tables 3 and 4 ). Women were older at the time of diagnosis of heart failure than men (71.9±10.6 years versus 68.1±10.6 years; p<0.001). Subjects were older at the diagnosis of heart failure in the later decades of this study (mean age at heart failure diagnosis, 57.3±7.6 years in the 1950s, 65.9±7.9 years in the 1960s, 71.6±9.4 years in the 1970s, and 76.4±10.0 years in the 1980s; p<0.001). These 652 individuals were followed for a mean of 3.9 years after the onset of heart failure (range, 0 days to 35.8 years; SD, 5.4 years). Five hundred Table 3 ). CHD was less common in women with heart failure than in men (OR, 0.55 after adjusting for age; 95% CI, 0.40-0.76), whereas preexisting VHD was more frequent in women (OR, 1.88; 95% CI, 1.23-2.88). In contrast, the frequency of heart failure attributed to HTN was similar in both sexes. CHD was a more commonly attributable cause of heart failure in the later decades (age-adjusted prevalence, 22% in the 1950s, 36% in the 1960s, 53% in the 1970s, and 67% in the 1980s; p<0.005), whereas VHD was a less frequent cause in the later decades (age-adjusted prevalence, 16% in the 1950s, 15% in the 1960s, 13% in the 1970s, and 10% in the 1980s; p<0.005). There was no significant change in the frequency of HTN as the attributable cause of heart failure during the four decades of observation.
Differences in Clinical Characteristics Between Heart Failure Cases
There were some noteworthy differences in the clinical characteristics among the CHF cases with different attributable causes (Table 4 ). In comparison with cases of CHF caused by VHD, subjects developing heart failure secondary to CHD had higher diastolic blood pressures at the last examination before the onset of heart failure (p<0.05) and were more likely to be male (p<O.OOS), diabetic (p<0.005), and previously hypertensive (p<0.05). CHF cases caused by CHD were older than cases caused by HTN and other or unknown causes (p<0.05 for both comparisons). Within the group with heart failure attributed to CHD, there was a significantly lower prevalence of prior myocardial infarction among women (87 cases, 57%) than men (157 cases, 80%), with a male: female odds ratio for myocardial infarction of 0.31 (95% CI, 0.19-0.52) after adjusting for age. As expected, subjects who developed heart failure attributed to HTN had higher systolic and diastolic blood pressures than individuals in the other three groups (overall Kruskal-Wallis x2, p<0.001 for both variables; p<0.001 for all comparisons). There was also a higher proportion of men among heart failure cases caused by CHD than among cases caused by HTN (p<0.05). Individuals who developed heart failure attributed to other or unknown causes were more likely to be current cigarette smokers than subjects with heart failure attributed to CHD, VHD, or HTN (overall x 2, p<0.05; p<0.05 for all three comparisons), and (by definition) they had lower systolic blood pressures (overall Kruskal-Wallis x2, p<0.001; p<0.01 for all three comparisons). Body mass index, a measure of obesity, at the examination before onset of heart failure was lower in heart failure cases caused by VHD than in cases caused by CHD (p<0.001). In addition, heart These individuals were also more likely to have radiographic generalized cardiac enlargement than subjects with heart failure caused by CHD or HTN (overall x2, p<0.001; p<O.00l for both comparisons). There were no significant differences between the four groups in antecedent heart rate or total cholesterol.
Survival After Onset of Heart Failure
Median survival after the onset of CHF was 1.66 years in men and 3.17 years in women. One-, 2-, 5-, and 10-year survival rates were 57%, 46%, 25%, and 11%, respectively in men. The corresponding survival rates in women were 64%, 56%, 38%, and 21% (Table 5) .
Impact ofsex and age. After adjusting for age, survival after the development of heart failure was better in women than in men (hazards ratio for mortality of women to men, 0.64; 95% CI, 0.54-0.77). Mortality increased with advancing age in both sexes (hazards ratio for men, 1.27 per decade of age; 95% CI, 1.09-1.47; hazards ratio for women, 1.61 per decade of age; 95% CI, 1.37-1.90; Figure 1 ). Further analysis suggested that in men but not women the mortality rate after the onset of heart failure increased at more than a simple exponential rate with advancing age. There was no evidence that any of the attributable causes of CHF significantly altered the effect of age on prognosis.
Impact of etiology of CHE. Among men, CHF attributed to VHD (age-adjusted hazards ratio for mortality, 1.68; 95% CI, 1.15-2.46; Figure 2 ) or other or unknown causes (age-adjusted hazards ratio for mortality, 1.69; 95% CI, 1.05-2.72) carried a particularly poor prognosis compared with heart failure secondary to CHD. In women, survival after the development of CHF was not affected by any of the attributable causes (Tables 5 and  6 ). Survival was, however, worse in diabetic women (age-adjusted hazards ratio for mortality, 1.70; 95% CI, 1.21-2.38) and women with prior definite electrocardio-graphic LVH (age-adjusted hazards ratio for mortality, 1.63; 95% CI, 1.08-2.45). None of the other clinical characteristics in Table 6 , including a history of HTN or antecedent blood pressure, was predictive of survival.
Temporal changes in CHF mortality. There was no significant temporal change in overall survival after the onset of CHF during the 40-year period of observation (Figure 3 ). In addition, there were no appreciable temporal improvements in survival in CHF attributed to CHD, VHD, or HTN. Survival excluding subjects with recent onset of CHE. When the analysis was restricted to the 237 men and 230 women who survived 90 or more days after the onset of heart failure, a population more comparable to those included in heart failure intervention trials, the median survival was 3.21 years in men and 5.39 years in women ( Table 7) . Among those surviving at least 90 days after the diagnosis of heart failure, the 1-year survival rates were 79% in men and 88% in women. Five-year survival rates for 90-day survivors were 35% and 53% in men and women, respectively. Adjusting for age, there was no significant difference in the distribution of cases among the four attributable cause groups or the two sexes between heart failure cases who died within 90 days of diagnosis and those who survived 90 or more days. In this restricted population, there was also no significant temporal change in survival after the onset of heart failure during the 40-year period of observation (age-adjusted hazards ratio for mortality for men, 0.98 per calendar decade; 95% CI, 0.80-1.19; age-adjusted hazards ratio for mortality for women, 0.99 per calendar decade; 95% CI, 0.77-1.29). Survival among 90-day survivors remained better in women than in men (ageadjusted hazards ratio for mortality of women to men, 0.55; 95% CI, 0.44-0.68). Increasing age continued to be associated with increased mortality (hazards ratio for men, 1.29 per decade of age; 95% CI, 1.07-1.56; hazards ratio for women, 1.71 per decade of age; 95% CI, 1.40-2.10). Discussion CHF remains a highly lethal condition, with a median survival of 1.7 years in men and 3.2 years in women. Our study reveals that CHF is more lethal in men than in women, and its prognosis is worse in elderly subjects of both sexes. In contrast to declining trends for CHD mortality,2'7 we have not yet observed a significant change in the prognosis of CHF during 40 years of follow-up of our unselected study population. This study has distinct advantages over prior studies of CHF prognosis. The Framingham Heart Study offers a large, unselected patient population with nearly equal numbers of male and female cases and uniform ascertainment of events over a 40-year follow-up period. We were able to examine survival after the diagnosis of heart failure in all our heart failure cases; in contrast, intervention trials and hospital-based referral series, although capable of following more cases, use selected populations of patients who survived the acute onset of CHF to achieve study entry. In addition, the antecedent patient data enabled us to attribute probable causes of heart failure in our 652 cases.
In 1971, McKee and his coworkers14 noted that the clinical course and prognosis of CHF were "surprisingly grim and not much better than those for cancer in general." During the period 1979-1984, the 5-year survival rate for all cancers was 50%, up from 39% during the years 1960-1963.16 In contrast, the prognosis of CHF did not change appreciably from 1948 to 1988. With 5-year survival rates of 25% in men and 38% in women, CHF carries a shorter life expectancy than many common malignancies including both Hodgkin's and non-Hodgkin's lymphomas, breast, colorectal, renal, and metastatic prostatic tumors. 16 Among our subjects, prognosis after the development of heart failure was more favorable in women than in men (hazards ratio, 0.64). This advantage persisted after controlling for age and attributable cause of heart failure. Controversy exists in the medical literature over sex differences in heart failure prognosis. Prior studies of CHF have found prognosis to be better in women, 14, 17, 18 better in men,19 or unrelated to sex.20-24 These clinical series were, however, subject to selection bias and had small sample sizes. The low proportion of women in these series would also reduce the statistical power for detecting sex differences in survival. In contrast, we were able to examine the prognosis of heart failure in 321 women and 331 men and thereby elucidate an unequivocal survival advantage in women.
Advancing age was a predictor of shortened survival in individuals with CHF, with a 27% increase in mortality per decade of advancing age in men and a 61% increase per decade in women. Higher heart failure mortality rates among older patients were also reported in some previous studies17,2526 but not in others.8,20-24,27-33 Our subjects were followed for up to 35.8 years after the development of heart failure and included individuals with recent myocardial infarction, unstable angina, or significant VHD. The longer follow-up period and the complete inclusion of all heart failure cases from the time of heart failure onset in the present study may have enhanced our statistical power to detect the negative impact of age on prognosis of heart failure.
Among men with CHF, survival was better in cases attributed to CHD or HTN than in those attributed to VHD (hazards ratio, 1.68 relative to CHD cases) or other and unknown causes (hazards ratio, 1.69 compared with CHD cases). Prognosis in our subjects with heart failure attributed to CHD was better than that of men with CHD in the placebo groups of medical intervention trials or in some clinical series,21,23,27,29 similar to those in two series2634 but worse than others. 24, 35 Unlike these studies, our survival statistics were calculated from the time of diagnosis of heart failure. In addition, our unselected study population, aged years, also included individuals who would have been excluded from intervention trials because of advanced age, acute myocardial infarctions, pulmonary edema, and uncontrolled or unstable angina. For example, the V-HeFT studies excluded individuals with a myocardial infarction within the previous 3 months. 35'36 When our analysis was restricted to subjects who survived at least 90 days after the diagnosis of heart failure, our results more closely resemble those from drug intervention studies. Specifically, the 1-year, 2-year, and 4-year survival rates for men in the placebo group in V-HeFT I were, respectively, 81%, 66%, and 46%. 35 In our study, the corresponding survival rates were 79%, 63%, and 45% in men who survived 90 or more days after the onset of heart failure but only 57%, 46%, and 32% among all men with heart failure. Among men with heart failure attributed to CHD, the 1-year and 2-year survival rates for the placebo group in V-HeFT I were 75% and 58%, respectively. Among our cases, the corresponding 1-year and 2-year survival rates were, respectively, 77% and 64% among 90-day survivors and 56% and 46% among all men with heart failure attributed to CHD.
Among women with CHF, diabetes mellitus and prior electrocardiographic LVH were harbingers of shortened survival, with a 70% and 63% increase in mortality, respectively. These results agree with prior findings from the Framingham Heart Study that showed increased risk of cardiovascular death and heart failure incidence in diabetic women. 37, 38 More recent data have suggested an anatomic basis for the decreased survival in diabetic women with heart failure. Echocardiographic studies have revealed an association between diabetes and left ventricular mass and wall thickness in women but not in men. 39 Using uniform ascertainment methods and clinical criteria for the diagnosis of overt CHF during a 40-year period of observation, we were unable to detect any temporal change in overall survival after the onset of heart failure or in the prognosis of heart failure caused by any of its attributed causes. However, there may have been imperceptible changes in the attributes of heart failure cases that could not be accounted for in these analyses. Since participants in the Framingham Heart Study were aging during the 40-year period of observation, it is difficult to determine whether the older age at diagnosis of heart failure in the later decades represents a delay in the onset of heart failure or merely aging of the underlying population at risk for heart failure. We are examining, in a separate investigation, the impact of temporal changes in the prevalences of CHD, VHD, HTN, and other conditions on the incidence of CHF.
Our observational study did not directly examine the impact of therapy on survival after the onset of heart failure; most of the follow-up period for our study occurred before the widespread use of vasodilators, angiotensin converting enzyme inhibitors, and cardiac transplantation.
The algorithm used for assigning attributable causes of CHF in this study is imperfect. Criteria were established to define attributable cause in a hierarchical manner, from the most severe and likely cause (i.e., CHD) to the least causal (HTN). Our definitions of CHD and VHD were based on clinical criteria, not on angiographic or echocardiographic data; hence, the possibility of misclassification exists. Additionally, since study participants were examined every 2 or more years, subjects may have, unbeknownst to us, developed HTN, VHD, or other comorbid conditions between the time of their last heart study visit and the onset of heart failure. However, unlike referral-based studies, we were able to take advantage of blood pressure determinations, medication histories, and physical examinations collected during 40 years of observation in assigning causes to cases of heart failure. Additional sources of error include missing data and incomplete follow-up. The great majority of subjects for our study were white; thus, our results may not be generalizable to individuals with heart failure from other racial or ethnic groups in which the causes of heart failure and prognosis after its onset may differ. Also, our study population consisted of subjects with overt CHF; hence, our findings may not be applicable to individuals with mild heart failure or subclinical left ventricular dysfunction.
There is no consensus on criteria required to establish a diagnosis of CHF. This study examined the survival of patients in whom heart failure was diagnosed on the basis of clinical criteria that have been previously vali-dated40 and are compatible with the presence of either diastolic or systolic dysfunction."142 Most prior heart failure intervention trials required a reduced left ventricular ejection fraction as an entry criterion32, 35, 36, 43 and therefore may be applicable only to patients with systolic heart failure. The prevalence of pure diastolic heart failure among patients with CHF is uncertain. Normal systolic function has been documented in 30-40% of patients with clinical heart failure."-"7 At least 20-40% of these individuals have findings suggestive of diastolic dysfunction on echocardiograms or radionuclide ventriculograms.4144, 46 The relative prognosis of diastolic versus systolic heart failure cannot be ascertained from this study. Nevertheless, the similar prognoses in our subjects who survived 90 days and in the placebo-treated subjects in V-HeFT I are striking. Heart failure with intact systolic function may carry a better prognosis than heart failure with depressed systolic function,48 but it is still associated with significant morbidity and mortality. 49 Despite advances in our treatment options for ischemic heart disease and HTN, heart failure remains a highly lethal condition. Better methods to prevent the development of heart failure in individuals with CHD, VHD, and HTN are needed. The encouraging results of newer interventions (e.g., hydralazine and long-acting nitrates, angiotensin converting enzyme inhibitors, coronary artery bypass grafting, valve replacement surgery, and cardiac transplantation) indicate that secondary preventative strategies can improve survival after the onset of CHF. Clearly, CHF is a heterogeneous disorder encompassing a constellation of symptoms that can result from a variety of pathophysiological processes reflecting both systolic and diastolic dysfunction. Further investigations are required to delineate the prognoses of different types of CHF and to evaluate the efficacy of specific treatments in various heart failure subgroups. More effective strategies for the primary and secondary prevention of CHF may in time alter both its incidence and prognosis.
